Biofuel Cell CGMs

Introduction to Biofuel Cell CGMs

A biofuel cell CGM is a continuous glucose monitor (CGM) that would get its electricity from the glucose it measures instead of from a battery. As of October 2026 it is still a laboratory idea. We searched FDA's 510(k) and premarket approval (PMA) databases and found no device named with the word "biofuel" [10][11]. The idea is worth understanding anyway, because it borrows the same enzyme chemistry that commercial sensors already rely on [7][8].

Principle of Operation

A biofuel cell is a fuel cell whose catalysts are enzymes, the proteins that speed up specific chemical reactions in living things. At one electrode, the anode, the enzyme glucose oxidase pulls electrons off glucose molecules [1]. At the other electrode, the cathode, a second enzyme passes those electrons to oxygen, which becomes water [4]. The electrons travelling between the two electrodes form an electric current.

Here's the part that turns a power source into a sensor. The power a biofuel cell delivers rises with the concentration of its fuel [4]. More glucose in the surrounding fluid means more output, so the output itself can serve as the glucose signal. Researchers call devices like this self-powered biosensors [4]. Our article on enzymatic biofuel cells for self-powered sensors goes further into the enzyme side.

Patents and Manufacturers

Most of the published work we found comes from university laboratories rather than CGM makers. In 2001, chemists at the Hebrew University of Jerusalem described "self-powered enzyme-based biosensors" [2]. Two years later the same group reported a glucose biofuel cell whose output could be switched on and off electrochemically [3]. A team at Université Grenoble Alpes in France has studied what it takes to keep a biofuel cell working inside the body, and traces the idea of drawing energy from body fluids back to a 1968 proposal [5]. We could not confirm which companies hold patents on biofuel-cell CGMs, so we don't name any here.

Dexcom's G7 and Abbott's FreeStyle Libre 3 Plus also measure glucose with glucose oxidase [7][8]. They run on conventional power, though. FDA's review of the FreeStyle Libre 3 Plus sensor describes a silver oxide battery [7].

Latest Product Lines and Comparison

As of October 2026, the Dexcom G7 and the FreeStyle Libre 3 Plus sensor are current prescription CGMs, and neither uses a biofuel cell. FDA's review of the Libre 3 Plus spells out how it works: the enzyme oxidizes glucose, electrons move to an electrode, and the strength of that current is proportional to the glucose level [7]. The G7 relies on the same glucose oxidase reaction [8]. FDA cleared the Libre 3 Plus sensor for up to 15 days of wear [7].

If you still have an original FreeStyle Libre 3 sensor in mind, note that Abbott discontinued it. Abbott kept the Libre 3 and Libre 2 sensors available only through September 30, 2025, and patients moving to the Plus sensors need a new prescription [9].

A fair comparison between these products and a biofuel-cell CGM will have to wait for clinical accuracy data. Without an FDA record, there is no labeled accuracy or wear time to compare against [10][11].

Effectiveness and Technology

Power output is the number that matters most, and it is small. The 2003 Hebrew University cell delivered at most 4.3 microwatts [3]. A 2025 review in IEEE Reviews in Biomedical Engineering found that the best enzymatic glucose fuel cell test reached 119 microwatts per square centimeter and lost 4% of its efficiency over 15 hours [6]. For scale, the same review puts the power needs of existing implanted devices between 10 microwatts and 100 milliwatts, with an expected service life of 10 years or more [6].

There is also a trade-off in the catalyst. Enzymes pick out glucose more precisely, while abiotic catalysts, made from reactive metals, hold up longer [6]. A second 2025 review names low power density, short operating life and the difficulty of miniaturizing as the main barriers to practical use [4].

Pitfalls, Warnings, and Issues

Enzymes wear out, and when they do, the signal drifts. One example from the 2025 biosensor review is a self-powered biofuel-cell sensor that measured lactate rather than glucose. Its power output fell by more than half within two weeks, and the reviewers concluded it would need recalibrating or replacing every two weeks [4].

That recalibration burden belongs to the prototypes. It doesn't describe current commercial CGMs: FDA lists the Dexcom G7 as factory calibrated with optional manual calibration [8], and describes the Libre 3 Plus sensor as factory calibrated with no fingerstick calibration required [7].

Compatibility with the body is the other open problem. The Grenoble team calls biocompatibility the major challenge in extending how long an implanted enzymatic biofuel cell lasts [5]. Cost and environmental impact are harder to judge, since there is no product yet to measure.

Conclusion

A biofuel cell CGM would power a sensor with the body's own glucose. As of October 2026, the published devices still produce too little power for too short a time [4][6]. Two questions decide whether that changes: can the enzymes survive a full wear period, and can a cell on or in the body stay compatible with the tissue around it? Until a design answers both with clinical data, biofuel cell CGMs remain a research topic rather than something you can be prescribed.